Best Infectious Diseases Companies in Washington, United States
The 31 best Infectious Diseases companies in Washington, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Adaptive Biotechnologies.
Our analysis of 50 Infectious Diseases companies
$7.1b in tracked funding; 59% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Infectious Diseases companies in Washington
| # | Company | Disclosed funding | Last round | Employees | Founded | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | Adaptive Biotechnologies Provider of clinical diagnostics, and drug discovery for immune diseases | $419M | 105 mo ago | 609 609 → 654 (+7%) | 2009 | Harlan Robins co-founder and chief Scientific Officer | 351 patents Immune repertoire sequencing and engineered T-cell receptor therapeutics for disease diagnostics and treatment | — |
| 2 | CytoDyn Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection 32Funding top 17%Growth top 35%Patents top 36%Innovation top 44% All 10 signals ▾Fundingtop 17% Growthtop 35% Patentstop 36% Innovationtop 44% Moatbottom 49% Globalbottom 36% Techbottom 35% Newsbottom 26% Marketbottom 25% Fin. healthbottom 24% Funding: Raised $250M across 23 rounds · 23 rounds over 17 yrs (1.4/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 32/100 | $250M | 8 mo ago | 12 12 → 23 (+92%) | 2002 | — | 107 patents CCR5-targeted biologics for HIV, cancer, NAFLD/NASH, and inflammatory disease treatment | — |
| 3 | Icosavax Developer of computationally designed VLP vaccines for treating multiple infections | $152M | 67 mo ago | 60 | 2017 | Adam Simpson Founder & CEO | 123 patents Influenza neuraminidase tetramer nanoparticle vaccine antigens and related peptide scaffolds | — |
| 4 | Curevo Developer of vaccines for the treatment of various diseases 29Funding top 25%Talent top 41%Moat top 43%Patents top 48% All 9 signals ▾Fundingtop 25% Talenttop 41% Moattop 43% Patentstop 48% Techtop 50% Innovationbottom 45% Globalbottom 39% Marketbottom 22% Newsbottom 18% Funding: Raised $86.0M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: Analyst team rating 4/5 · 1 named leader on record rank vs industry peers · Fliar Intelligence Index 29/100 | $86M | 20 mo ago | 8 | 2017 | George Simeon CEO | 3 patents Formulating herpes zoster preventive vaccines and combination immunogenic vaccine technologies. | — |
| 5 | Lumen Developer of biological drugs for the treatment of infectious diseases | $68M | 37 mo ago | 67 | 2011 | Brian Finrow CEO & Founder | — | — |
| 6 | Theraclone Sciences Discovering human monoclonal antibodies for safe and effective therapeutic product development | $61M | 138 mo ago | 19 | 2004 | Clifford J Stocks CEO | 225 patents Broadly neutralizing anti‑HIV‑1 envelope glycoprotein monoclonal antibody therapeutics | — |
| 7 | Cardeas Pharma Developer of inhaled antibiotics for DR gram negative infections | $49M | 139 mo ago | 2 | 2010 | — | — | — |
| 8 | Tune Therapeutics Developer of cell and gene therapy by using the epigenomic platform | $40M | 44 mo ago | 89 | 2009 | Akira Matsuno Co-Founder | — | — |
| 9 | HDT Bio Developer of immunotherapy for the treatment of cancer & infectious diseases | $31M | 17 mo ago | 32 32 → 54 (+69%) | 2018 | — | — | — |
| 10 | Etubics Therapeutic vaccines for cancer | $23M | 145 mo ago | 14 | 2005 | — | 160 patents Adenovirus vector manufacturing for multi‑antigen vaccines and cancer immunotherapy. | — |
| 11 | Koronis Pharmaceuticals Developing innovative biotechnology platforms for viral research and therapeutics | $21M | 133 mo ago | 4 | 1998 | — | — | — |
| 12 | InBios Innovating immunodiagnostics for infectious diseases, improving global health outcomes | $18M | 18 mo ago | 73 | 1996 | Estela Raychaudhuri CEO & President | 24 patents Rapid lateral flow immunoassays for detecting viral and parasitic infections | — |
| 13 | Helix BioMedix Biotech firm pioneering bioactive peptides for pharmaceutical and cosmeceutical markets | $11M | 87 mo ago | 4 | 1988 | Robin Carmichael President & CEO | 234 patents Therapeutic short peptides for skin regeneration, wound healing, and UV protection | — |
| 14 | Blue Tech Reimagine inventions, build companies, and solve global challenges | $10M | 124 mo ago | 53 | 2015 | — | — | — |
| 15 | Tria Bioscience Innovating hearing technology for biomedical equipment manufacturers worldwide | $9M | 97 mo ago | — | 2009 | Christopher Clegg Founder & President | — | — |
| 16 | Micronics Point-of-care microfluidics devices for rapid testing | $9M | 192 mo ago | 35 | 1996 | — | 221 patents Microfluidic sample prep, nucleic acid analysis, and advanced filtration technologies | — |
| 17 | Anavasi Diagnostics Manufacturer of molecular detector for COVID-19 | $6M | 60 mo ago | 30 | 2020 | Minh Duong Co-Founder | — | — |
| 18 | Immunexpress Molecular diagnostics for the detection of sepsis. | $6M | 85 mo ago | 16 | 2006 | — | — | — |
| 19 | Iasis Molecular Sciences Molecular solutions provider, launching soon with subscription-based updates | $5M | 25 mo ago | 2 | 2008 | — | — | — |
| 20 | Abacus Bioscience Developer of immunotherapeutics for treating cancer and viral diseases | $4M | 45 mo ago | 7 | 2015 | Edward Clark Founder and Chair | — | — |
| 21 | Inventprise Developer of conjugate vaccines designed to prevent infectious diseases globally | $4M | 59 mo ago | 88 88 → 105 (+19%) | 2012 | Subhash Kapre Founder | 138 patents Oral vaccine adjuvants and PEGylated polysaccharide conjugate vaccine technologies. | — |
| 22 | MalarVx Developing innovative malaria vaccines using RNA technology and in vitro culture systems | $1M | 73 mo ago | 5 | 2012 | — | 3 patents Malaria vaccine compositions, delivery devices, and sterile protection methods | — |
| 23 | ID Genomics Diagnostics for drug resistant infections. | $736K | 62 mo ago | 3 | 2012 | — | 149 patents Molecular diagnostics for cardiovascular biomarkers and advanced tissue sample processing technologies. | — |
| 24 | Briotech Developer of hypochlorous disinfection solution | $490K | 19 mo ago | 27 27 → 43 (+59%) | 2013 | Cynthia Varela Founder | 32 patents On-demand, remote-controlled production of pure hypochlorous acid for disinfection and medical use | — |
| 25 | Photonic BioSystems Developer of liquid handling, optical sensing, and bioassay systems for microbial detection | $281K | 182 mo ago | — | 1995 | David Putnam CEO & President | 30 patents Microfluidic bioanalysis platforms with integrated optical/chemical sensors for rapid assays | — |
| 26 | Phoresa Developing rapid, accurate diagnostic tests for infectious diseases, improving patient care | $225K | 124 mo ago | — | 2014 | Mark Borysiak Co-Founder | — | — |
| 27 | Attodx Developer of a pathogen detection technology for detecting viable bacterial pathogens | $183K | 139 mo ago | — | 2009 | James Davie CEO | — | — |
Top 12 Infectious Diseases companies in Washington
#1
Public · Vancouver, Washington · founded 2002 · 12 employees$249.7Mraised▾
Developer of humanized monoclonal antibodies for the treatment and prevention of HIV infection. It offers lead candidate, PRO 140,for HIV with demonstrated antiviral activity in men. PRO 140 blocks the HIV co-receptor CCR5 on T-cells that prevent viral entry.
- Mar 2026Post IPO$17.5M
- Jan 2026Post IPO$18.6M
- Apr 2022Post IPO$1.9M
- Dec 2021Post IPO$11.4M
#2
Series B · Seattle, Washington · founded 2017 · 8 employees$86Mraised▾
Developer of vaccines for the treatment of various diseases. The company's product pipeline includes CRV-101, for Herpes Zoster, CRV0-102 used against chicken pox. Other products of the company include CRV-201 used against the respiratory syncytial virus.
- Mar 2025Series B$110M
- Nov 2022Series A$26M
- Jan 2022Series A$60M
#3
Seed · Seattle, Washington · founded 2018 · 32 employees$30.6Mraised▾
HDT Bio is a developer of immunotherapy for the treatment of cancer & infectious diseases. It enhances the body's immunity power to fight against cancer disease. It increases tumor junctions and improves the disruptive capability. It helps in the tumor penetrance and therefore improves the efficacy, of diverse therapeutics including chemotherapeutics like Paclitaxel, Doxil, Cisplatin, antibodies, oncolytic viruses, and cell therapies. It helps in the treatment of breast cancer, ovarian cancer, and many more. It also provides solutions for pathogen agnostic therapeutics that offer solutions against gram-positive and gram-negative bacteria.
- May 2025Grant (prize money)$2.7M
- May 2025Grant (prize money)$1.6M
- May 2025Grant (prize money)$2.2M
- Apr 2025Grant (prize money)$2M
#4
Funding Raised · Seattle, Washington · founded 1996 · 73 employees$18Mraised▾
Innovating immunodiagnostics for infectious diseases, improving global health outcomes. This biotechnology company specializes in the design, development, and manufacture of high-quality immunodiagnostic devices for infectious diseases and biothreats. They strive to improve health outcomes globally by providing superior quality products that are accurate, easy to use, and cost-effective. Their team of scientists and engineers have extensive experience in developing and manufacturing in vitro diagnostic tests, with expertise in infectious diseases. They offer reliable and practical solutions for challenging infectious disease diagnoses. They develop proprietary technologies used to create rapid and ELISA-based immunodiagnostic assays. They also specialize in the development and manufacture of highly specific and well-characterized antibodies and antigens for use in infectious disease research. They are a total solution company with expertise in all facets of the product pipeline, from discovery to application, partnering with private companies, federal laboratories, and academia to bring customers the best scientific solutions for their diagnostic needs. They offer assay development
- May 2025Grant (prize money)$2M
- May 2024Grant (prize money)$1000K
- Nov 2022Grant (prize money)$100K
- Mar 2020Grant (prize money)$598K
#5
Series C · Seattle, Washington · founded 2011 · 67 employees$68Mraised▾
Lumen Bioscience is a developer of biological drugs for the treatment of infectious diseases. It has developed drugs candidate for the treatment of diarrhea, norovirus enteritis, norovirus enteritis, malaria, C. difficile Colitis, and others. It is also developing drugs for the treatment of autoimmune diseases of the GI tract including celiac disease, ulcerative colitis, and Crohn’s disease, and many more.
- Sep 2023Series C$33M
- Sep 2020Grant (prize money)—
- Sep 2020Series B$16M
- Jul 2018Grant (prize money)$96.2K
#6
Public · Seattle, Washington · founded 2009 · 609 employees$419.1Mraised▾
Provider of clinical diagnostics, and drug discovery for immune diseases. The company's immune profiling sequencing technology immunoSEQ enables the characterization of the immune system, helping scientists & clinicians in research and drug development. The company also offers clonoSEQ for monitoring Minimal Residual Disease (MRD) in blood-based cancers. Also, develops cell therapies, vaccines, and antibody molecules for infectious diseases.
- Jan 2018Series F—
- May 2015Series F$195.1M
- Jan 2015Series E$94M
- Aug 2014Grant (prize money)$115.4K
#7
Funding Raised · Spokane, Washington · founded 2008 · 2 employees$5.2Mraised▾
Molecular solutions provider, launching soon with subscription-based updates. This company is poised to offer innovative solutions in the molecular space. While specifics are under wraps, the "launching soon" messaging suggests an imminent unveiling of their offerings. The subscription model hints at ongoing value and continuous updates for their user base. The company is focused on providing molecular solutions, indicating a commitment to scientific advancement and potentially impacting various industries. Sign-up for updates suggests a desire to build a community and keep potential customers informed about their progress. This approach fosters anticipation and allows the company to cultivate relationships before their official launch. The use of cookies indicates a focus on user experience and data-driven optimization of their website.
- Sep 2024Grant (prize money)$687K
- Jan 2022Grant (prize money)$1.2M
- Sep 2021Grant (prize money)$225.1K
- Sep 2021Grant (prize money)$225K
#8
Series A · Everett, Washington · founded 2013 · 27 employees$490Kraised▾
Developer of hypochlorous disinfection solution. The company produces a highly purified formulation of hypochlorous called BrioHOCl, which is used to kill microbes and is also used as a disinfectant.
- Apr 2025Series A$6M
- Aug 2021Seed$40K
- Oct 2020Seed$50K
- Sep 2020Seed—
#9
Acquired · Seattle, Washington · founded 2017 · 60 employees$152Mraised▾
Developer of computationally designed VLP vaccines for treating multiple infections. The company licensed technology offers proteins that can self-assemble into virus-like particles (VLPs), for its leading candidate IVX-121, which is a vaccine for the respiratory syncytial virus and leading to improved neutralizing responses in humans. The company is also working on RSV and SARS-CoV-2 vaccine development.
- Apr 2021Series B$100M
- Oct 2020Grant (prize money)$6.5M
- Oct 2019Series A$52M
- Seed—
#10
Series B · Seattle, Washington · founded 2009 · 89 employees$40Mraised▾
Developer of cell and gene therapy by using the epigenomic platform. The company has an epigenome editing and gene regulation platform to develop therapeutics for complex diseases without altering the DNA sequence.
- Mar 2023Series B$182.4M
- Dec 2021Series A$40M
#11
Series B · Seattle, Washington · founded 2004 · 19 employees$61.2Mraised▾
Discovering human monoclonal antibodies for safe and effective therapeutic product development. The company's comprehensive screening technology rapidly identifies rare antibodies evolved to cure infection and fight disease. For over a decade, the company perfected its platform technology to discover these human monoclonal antibodies for development as safe and effective therapeutic products. The company focuses on identifying and developing human antibodies with the potential to address unmet medical needs. The company's technology platform enables the discovery of antibodies with unique properties and therapeutic potential. The company is dedicated to advancing the field of antibody therapeutics and improving patient outcomes.
- May 2015Series B$3.1M
- Jul 2013Series B$6M
- Mar 2013Venture Debt$6M
- Mar 2013Series B$8M
#12
Deadpooled · Seattle, Washington · founded 2010 · 2 employees$49Mraised▾
Cardeas Pharma is a US-based, early stage biopharma developing inhaled antibiotics for DR gram negative infections. The company is developing an antibiotic formulation of two drugs with synergistic activity against highly resistant Gram-negative Bacteria. The combination product consists of two investigational drug product components: Amikacin Inhalation Solution and Fosfomycin Inhalation Solution, and the PARI Investigational eFlow Inline system, a single-patient-use, vibrating plate nebulizer that creates small, uniform aerosol droplets intended to deliver the drug to the small airways and alveoli. The system passed in a Phase 1b clinical study in patients with ventilator pneumonia. A Phase 2 clinical study is ongoing.
- Apr 2015Series B$37.5M
- Sep 2012Series A$10.5M
- Feb 2011Seed$1M
- Aug 2010Seed$20.1K
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Infectious Diseases coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding flat · growth falling
How research on Diagnostics in Washington is moving
A read on the academic research around Diagnostics in Washington — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 308 papers.
- University of Washington147
- Washington University in St. Louis85
- George Washington University42
- Washington State University19
- University of Washington Medical Center7
- Liquid biopsy1→7
- Virology1→5
- Polymerase chain reaction1→4
- Loop-mediated isothermal amplification1→3
- Multiplex1→3
- Liquid biopsy6→25
- Biopsy2→10
- Internal medicine1→7
- Circulating tumor cell3→7
- Point of care7→11
- Liquid biopsy1→9
- Biopsy1→7
- Malaria2→6
- Internal medicine2→5
- Test (biology)1→3
Common questions
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.